The company raised $74.5 million in a series B financing round last December, with which it hopes to study its RAF inhibitor in various cancers with non-V600 BRAF mutations.
PLX8394 is currently being studied in a Phase I/II trial of BRAF-mutated tumors, and Novellus plans to use its next-generation sequencing-based FACT assay to help further develop the drug.
Based on the finding that 80 percent of low-grade glioma patients saw their tumors shrink, researchers suggested that BRAF inhibitors may be useful in earlier lines of treatment.
In two studies, researchers showed the benefit of combining Tecentriq, Cotellic, and Zelboraf and sticking with continuous versus intermittent dosing of targeted drugs.
Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.
In a study published in the Journal of Clinical Oncology, partial responses were observed in patients with BRAF V600-mutated and KRAS-mutated solid tumors.
The Phase I trial, which will focus on studying BRAF-mutated solid tumors, has enrolled its first patient in Australia and will soon expand to sites in the US.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
